| Symbol | TLSI |
|---|---|
| Name | TRISALUS LIFE SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 6272 W 91ST AVE, WESTMINSTER, Colorado, 80031, United States |
| Telephone | +1 888 - 321-5212 |
| Fax | — |
| — | |
| Website | https://www.trisaluslifesci.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001826667 |
| Description | TriSalus Life Sciences was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our companyâs heritage is in the development of devices for our Pressure-Enabled Drug Deliveryâ"¢ (PEDDâ"¢) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy. Additional info from NASDAQ: |
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Read moreTriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Read moreTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Read moreTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Read moreNew Form SCHEDULE 13G/A - TriSalus Life Sciences, Inc. <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001999371-26-014465 <b>Size:</b> 15 KB
Read morePatience David 🔴 sold 14.7K shares of TriSalus Life Sciences, Inc. (TLSI) at $4.46 Transaction Date: Jul 01, 2026 | Filing ID: 047217
Read moreDirector Szela Mary T 🟢 acquired 4.0K shares of TriSalus Life Sciences, Inc. (TLSI) at $3.87 Transaction Date: Jun 30, 2026 | Filing ID: 046519
Read moreMarshak Richard 🟢 acquired 561 shares of TriSalus Life Sciences, Inc. (TLSI) at $3.87 Transaction Date: Jun 30, 2026 | Filing ID: 046507
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07791446 | End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Me… | Na | Liver Metastases | Not_Yet_Recruiting | 2026-11-01 | 2029-11-01 | ClinicalTrials.gov |
| NCT07444645 | PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery An… | Na | Tumor | Not_Yet_Recruiting | 2026-08-01 | 2030-07-31 | ClinicalTrials.gov |
| NCT06868459 | Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of … | — | Hyperthyroidism; Goiter | Enrolling_By_Invitation | 2025-04-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT06710223 | Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and… | Phase1 | Hepatocellular Carcinoma | Active_Not_Recruiting | 2025-01-03 | 2027-12-01 | ClinicalTrials.gov |
| NCT06204159 | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery | Na | Hepatocellular Carcinoma | Active_Not_Recruiting | 2024-02-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05743842 | TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90… | Na | Liver Cancer | Active_Not_Recruiting | 2023-03-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade fo… | Phase1 | Locally Advanced Pancreatic Adenocarcinoma | Active_Not_Recruiting | 2023-03-01 | 2027-10-01 | ClinicalTrials.gov |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization | Na | Uterine Bleeding | Terminated | 2023-02-09 | 2025-01-20 | ClinicalTrials.gov |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver … | Phase1 | Hepatocellular Carcinoma | Terminated | 2022-03-02 | 2024-07-31 | ClinicalTrials.gov |
| NCT05128032 | Pressure-enabled Delivery in Radioembolization (TriNav Study) | Na | Liver Cancer | Completed | 2022-03-01 | 2026-07-16 | ClinicalTrials.gov |
| NCT04935229 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (P… | Phase1 | Metastatic Uveal Melanoma in the Liver | Terminated | 2021-08-02 | 2024-07-17 | ClinicalTrials.gov |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Adv… | Phase1 | Pancreatic Adenocarcinoma | Withdrawn | 2019-12-23 | 2021-05-04 | ClinicalTrials.gov |
| NCT03007732 | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With … | Phase2 | Prostatic Neoplasms | Completed | 2017-05-17 | 2025-03-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard End Hole Microcatheter | Other | Approved | Liver Metastases | NOT_YET_RECRUITING | NCT07791446 |
| The TriNav Infusion Systems | Other | Approved | Liver Metastases | NOT_YET_RECRUITING | NCT07791446 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06710223 |
| PEDD device | Device | Approved | Liver Cancer | COMPLETED | NCT05128032 |
| Standard microcatheter | Other | Approved | Liver Cancer | COMPLETED | NCT05128032 |
| TACE Catheters | Other | Approved | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06204159 |
| TriSalus Infusion System | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| FOLFIRINOX | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| FOLFIRI | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| TriNaV | Other | Approved | Uterine Bleeding | TERMINATED | NCT06106633 |
| TACE Catheters | Other | Approved | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06204159 |
| anti-PD-1 | Other | Phase PHASE1 | Locally Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05607953 |
| SD-101 | Other | Phase PHASE1 | Locally Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05607953 |
| Data Collection | Other | Preclinical | Hyperthyroidism; Goiter | ENROLLING_BY_INVITATION | NCT06868459 |
| Nivolumab and Relatlimab | Other | Phase PHASE1 | Metastatic Uveal Melanoma in the Liver | TERMINATED | NCT04935229 |
| Ipilimumab | Other | Phase PHASE1 | Metastatic Uveal Melanoma in the Liver | TERMINATED | NCT04935229 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Uveal Melanoma in the Liver | TERMINATED | NCT04935229 |
| SD-101 | Other | Phase PHASE1 | Metastatic Uveal Melanoma in the Liver | TERMINATED | NCT04935229 |
| Ipilimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| Nivolumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Prednisone | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Abiraterone Acetate | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Leuprolide acetate | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| SD-101 | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Pembrolizumab | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Y90-radioembolization procedure | Procedure | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05743842 |
| Angiogram | Other | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05743842 |
| TriSalus™ TriNav™Infusion System | Other | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05743842 |
| PEDD device | Device | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05128032 |
| Standard microcatheter | Other | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05128032 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Durvalumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | Drug | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| SD-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Y90 Microsphere Therapy | DEVICE | Approved | Tumor | NOT_YET_RECRUITING | NCT07444645 |
| Data Collection | OTHER | Preclinical | Hyperthyroidism; Goiter | ENROLLING_BY_INVITATION | NCT06868459 |
| Durvalumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Tremelimumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Cryotherapy | DEVICE | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| TACE Catheters | DEVICE | Approved | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06204159 |
| TriNaV | DEVICE | Approved | Uterine Bleeding | TERMINATED | NCT06106633 |
| Y90-radioembolization procedure | PROCEDURE | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05743842 |
| TriSalus™ TriNav™Infusion System | DEVICE | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05743842 |
| anti-PD-1 | BIOLOGICAL | Phase PHASE1 | Locally Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05607953 |
| PEDD device | DEVICE | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05128032 |
| Standard microcatheter | DEVICE | Approved | Liver Cancer | ACTIVE_NOT_RECRUITING | NCT05128032 |
| Nivolumab and Relatlimab | BIOLOGICAL | Phase PHASE1 | Metastatic Uveal Melanoma in the Liver | TERMINATED | NCT04935229 |
| Ipilimumab | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |
| TriSalus Infusion System | DEVICE | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| FOLFIRINOX | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| FOLFIRI | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | WITHDRAWN | NCT04270929 |
| Stereotactic Body Radiation Therapy | RADIATION | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Prednisone | DRUG | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Abiraterone Acetate | DRUG | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| Leuprolide acetate | DRUG | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT03007732 |
| SD-101 | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT06710223 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05220722 |